Hemangiopericytomas grade II are not benign tumors

Area of Science:

• Neuro-oncology
• Surgical Oncology
• Radiation Oncology

Background:

• Hemangiopericytomas (HPs) of the central nervous system are rare, aggressive tumors with high recurrence and metastasis rates.
• Both differentiated (WHO grade II) and anaplastic (WHO grade III) HPs can exhibit underestimated aggressiveness.
• Understanding tumor behavior and treatment efficacy is crucial for improving patient outcomes.

Purpose of the Study:

• To describe the tumor behavior of central nervous system hemangiopericytomas (HPs).
• To evaluate the impact of radio- and chemotherapy on tumor control in relation to WHO grade.
• To assess the effectiveness of surgical resection extent on recurrence and metastasis.

Main Methods:

• Retrospective study of 15 patients with cerebral and spinal HPs.
• Analysis of tumor behavior, including recurrence and metastasis rates.
• Evaluation of the effects of surgical resection, radiotherapy, and chemotherapy based on WHO classification (grade II and III).

Main Results:

• Complete surgical resection was achieved in 60% of cerebral and 25% of spinal HPs.
• Local recurrences occurred in 20% of patients, with no recurrences or metastases seen after complete resection of grade II HPs.
• Radiotherapy showed partial effectiveness in tumor control, while chemotherapy demonstrated no effect.

Conclusions:

• Radical surgical resection is the most effective treatment for controlling HP tumor progress.
• Radiotherapy is indicated for subtotal resections or anaplastic (WHO III) tumors.
• Screening for metastases is recommended during initial diagnosis and after recurrence, regardless of tumor grade.